Nancy Rigotti, MD
Founding Director, Tobacco Research & Treatment Center, Associate Chief, Division of General Internal Medicine, Massachusetts General Hospital. Professor of Medicine, Harvard Medical School
Contact: firstname.lastname@example.org (617) 724-3548
Dr. Rigotti is a general internist with research training and expertise in clinical epidemiology, clinical trials, outcomes research, implementation science, and tobacco control policy. She is Professor of Medicine at Harvard Medical School and MGH, Associate Chief of the MGH Division of General Internal Medicine, and Past President of both the Society for Nicotine and Tobacco Research and the Society of General Internal Medicine. Her research goal for more than 30 years has been to reduce the toll of tobacco-related disease by identifying innovative tobacco cessation treatments, by promoting delivery of effective tobacco cessation treatment in the health care delivery system in the U.S. and globally, and by evaluating the impact of tobacco control public policies. Using randomized controlled trials and observational studies, she has demonstrated the effectiveness of tobacco treatment interventions offered to smokers in the context of hospitalization, outpatient primary care, prenatal care, and specialty practice (e.g., cardiology, oncology), as well as system-level population health outreach. She has recently extended this work to incorporate health care system interventions to other addictive drug use. Dr. Rigotti has conducted clinical trials of FDA-approved or investigational smoking cessation pharmacotherapies, including bupropion, varenicline, rimonabant, and a nicotine vaccine. Dr. Rigotti served as a scientific editor for the 1989 U.S. Surgeon General’s Report on Smoking. Her early epidemiologic studies demonstrated the dramatic rise in tobacco use by young adults in the 1990s, bringing attention to a previously-ignored group. She conducted some of the first formal evaluations of smoke-free public policies and restrictions on youth access to tobacco. More recently, she has studied tobacco cessation interventions globally and investigated the impact of electronic cigarettes on smoking cessation. Dr. Rigotti founded and directs the MGH’s multi-disciplinary Tobacco Research and Treatment Center. It combines an institutionally-funded MGH clinical service with an externally-funded research group that conducts projects to identify and implement effective tobacco cessation interventions in the health care delivery system. Her pioneering role and outstanding research was recognized in 2015 with the highest award for research given by the Society of General Internal Medicine, the John Eisenberg National Award for Career Achievement in Research. She is also an elected member of the American Association of Physicians. She served on the Institute of Medicine committee creating the 2015 report on agent-based modeling for tobacco control and the upcoming 2018 National Academies of Science, Engineering, and Medicine’s FDA-commissioned report on the health risks and benefits of electronic cigarettes. She has been continuously funded as PI for over 30 years on grants awarded by NIDA, NHLBI, NCI, NIMH and foundations. Dr. Rigotti also has extensive mentoring experience previously supported by a K24; she has mentored over 30 trainees from internal medicine, pediatrics, family medicine, and psychiatry. Many of her trainees have secured career development awards and R01s and have progressed to leadership positions in academic medicine in the U.S. and abroad. Dr. Rigotti also serves as Director of the MGH’s Office of Women’s Careers which supports academic career advancement for female faculty.
Comparative effectiveness of post-discharge strategies for hospitalized smokers
NHLBI R01 HL111821 2012-22
The primary goal is to test an innovative strategy to efficiently sustain patient contact after discharge by streamlining the delivery of post-discharge smoking interventions to maximize their uptake
A proactive population health strategy to offer tobacco dependence treatment to smokers in a primary care practice network
Pfizer Independent Grants for Learning and Change 2015-18
The primary goal is to create and test a novel population health strategy to increase the delivery of tobacco dependence treatment.
Career development program in substance use and addiction medicine
NIDA 1K12DA043490 2017-22
The goal of this Mentored Award is to develop a multidisciplinary program at the Massachusetts General Hospital that will support intensive, mentored training and career development of promising post-doctoral clinician-scientists who aim to establish independent research programs in patient oriented addiction research.
Extended care for smoking cessation following psychiatric hospitalization
NIH/NIMH 1 R01 MH104562 (Brown / Rigotti, multiple PIs) 2014-19
RCT testing the effectiveness of a multi-modal smoking cessation program for smokers being discharged from an inpatient psychiatric hospital.